Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection

3Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Negative checkpoint regulators (NCRs) reduce the T cell immune response against self-antigens and limit autoimmune disease development. V-domain Ig suppressor of T cell activation (VISTA), a novel immune checkpoint in the B7 family, has recently been identified as one of the NCRs. VISTA maintains T cell quiescence and peripheral tolerance. VISTA targeting has shown promising results in treating immune-related diseases, including cancer and autoimmune disease. In this review, we summarize and discuss the immunomodulatory role of VISTA, its therapeutic potential in allergic, autoimmune disease, and transplant rejection, as well as the current therapeutic antibodies, to present a new method for regulating immune responses and achieving durable tolerance for the treatment of autoimmune disease and transplantation.

Cite

CITATION STYLE

APA

Zheng, M., Zhang, Z., Yu, L., Wang, Z., Dong, Y., Tong, A., & Yang, H. (2023). Immune-checkpoint protein VISTA in allergic, autoimmune disease and transplant rejection. Frontiers in Immunology. Frontiers Media SA. https://doi.org/10.3389/fimmu.2023.1194421

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free